Skip to main content
. 2010 Mar 31;84(12):5986–5996. doi: 10.1128/JVI.02563-09

FIG. 1.

FIG. 1.

Comparative magnitude and anatomic distribution of transgene expression and vaccine-elicited cellular immunity following i.m. and i.n. rAd immunization. (A) BALB/c mice (n = 12/group) were immunized by the i.m. or i.n. route with 109 VP rAd5HVR48-luc. In vivo luciferase gene expression was quantitated at various time points following immunization using high-sensitivity in vivo imaging. (B) C57BL/6 mice (n = 4/group) were immunized by the i.m. or i.n. route with 109 VP rAd5HVR48-Gag. At week 2 following immunization, the magnitude and distribution of vaccine-elicited Gag-specific CD8+ T-lymphocyte responses were determined using Db/AL11 tetramer binding assays. (C) OT-1 CD8+ T lymphocytes (3 × 106) were labeled with CFSE and adoptively transferred to naïve, CD45-congenic recipients (n = 4/group). Mice were immunized by the i.m. or i.n. route with 109 VP rAd5-Ova, and OT-1 CD8+ T-lymphocyte proliferation, as indicated by CFSE dilution, was assessed at multiple anatomic sites at day 3 following immunization. (D) (Left) BALB/c mice (n = 8/group) were immunized i.m. with 109, 108, or 107 VP rAd5HVR48-luc, and transgene transduction was assessed by in vivo imaging. (Right) C57BL/6 mice (n = 4/group) were immunized i.m. with 108 or 107 VP rAd5-HVR48-Gag. Gag-specific CD8+ T-lymphocyte responses were determined at day 14 following immunization using a Db/AL11 tetramer binding assay. The error bars represent standard errors (SE).